C22 MRSA- the Superbug
The researchers identified C22 as the dominant strain of MRSA which develops and maintains multi-drug resistance and which adapts to persist on hospital surfaces. According to author Dr. Lindsay, “studying the dynamic of how MRSA bacteria strains evolve in hospitals in response to infection control and antibiotic prescribing, is essential to the process of determining which strains are likely to have the best long-term outcomes.”
The bacteriophage is a potential anti-MRSA measure. A bacteriophage is a virus that kills bacteria and could counter intractable MRSA infections in patients. Dr. Lindsay told Decoded Science that, “Bacteriophage has potential to combat MRSA, but still needs substantial development before a product is likely to reach the market.”
MRSA Study Highlighted Reduced Infection Rates
This study examined whether improved infection control measures contributed to this decrease in MRSA infection. However, during a four-year period, the only major reduction in MRSA infection rates coincided with the reduction in ciprofloxacin prescriptions. In fact, the only measure that appreciably reduced deadly MRSA infection was the reduction of prescription antibiotics.
World Health Organization. MRSA: Antimicrobial Resistance. (2012). Accessed October 21, 2012.
Gwenan M. Knight, G., Budd, E., Whitney, L., Thornley, A., Al-Ghusein, H., Planche, T., Lindsay, J. Shift in dominant hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) clones over time. (2012). Journal of Antimicrobial Chemotherapy. Accessed October 21, 2012.
United States CDC. MRSA Statistics 2010. (2011). Accessed October 21, 2012.
Irish Health Service Executive. IrishHealth,22 Babies infected with MRSA. (2012). Accessed October 21,2012.
Pages: 1 2